Savient sells gout med to Crealta
Pending court approval, Savient's orphan drug Krystexxa will join Crealta Pharmaceuticals' drug portfolio.
Savient announced the deal for its refractory chronic gout medication Wednesday.
The $120.4-million sale is part of a bankruptcy auction. The companies expect the court to weigh in on Friday.